Summary
11.55 -0.08(-0.65%)09/27/2024
Viatris Inc (VTRS)
Viatris Inc (VTRS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.77 | 1.58 | -1.28 | 10.11 | -2.39 | 20.39 | -36.88 | 882.82 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.55 | |
| Open | 11.64 | |
| High | 11.68 | |
| Low | 11.50 | |
| Volume | 4,538,265 | |
| Change | -0.09 | |
| Change % | -0.77 | |
| Avg Volume (20 Days) | 7,191,926 | |
| Volume/Avg Volume (20 Days) Ratio | 0.63 | |
| 52 Week Range | 8.75 - 13.62 | |
| Price vs 52 Week High | -15.23% | |
| Price vs 52 Week Low | 31.94% | |
| Range | -0.82 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 13,869 | |
| EBIDTA | 6,664,800,256 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 20.38 | |
| Book Value | 17.4810 | |
| Earnings Per Share | -1.7150 | |
| EPS Estimate Current Quarter | 0.8800 | |
| EPS Estimate Next Quarter | 0.8700 | |
| EPS Estimate Current Year | 3.7100 | |
| EPS Estimate Next Year | 3.7200 | |
| Diluted EPS (TTM) | -1.7150 | |
| Revenues | ||
| Profit Marging | -0.1119 | |
| Operating Marging (TTM) | 0.1326 | |
| Return on asset (TTM) | 0.0326 | |
| Return on equity (TTM) | -0.1141 | |
| Revenue TTM | 17,168,199,680 | |
| Revenue per share TTM | 15.3280 | |
| Quarterly Revenue Growth (YOY) | 0.5260 | |
| Quarterly Earnings Growth (YOY) | -0.2830 | |
| Gross Profit (TTM) | 4,780,000,000 | |
| Dividends | ||
| Dividend Share | 0.3300 | |
| Dividend Yield | 0.0263 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 3.3557 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.7265 | |
| Revenue Enterprise Value | 2.2216 | |
| EBITDA Enterprise Value | 9.8600 | |
| Shares | ||
| Shares Outstanding | 1,209,389,952 | |
| Shares Float | 1,205,801,518 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.25 | |
| Institutions (%) | 75.41 | |
09/18 11:30 EST - prnewswire.com
Viatris Announces the Pricing Terms of Maximum Tender Offer
PITTSBURGH , Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined below) (such increased maximum aggregate principal amount, the "Maximum Tender Cap").
Viatris Announces the Pricing Terms of Maximum Tender Offer
PITTSBURGH , Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined below) (such increased maximum aggregate principal amount, the "Maximum Tender Cap").
09/17 20:45 EST - prnewswire.com
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
PITTSBURGH , Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") and that UAS has increased the maximum aggregate principal amount for the Maximum Tender Offer from up to a maximum aggregate principal amount of $450,000,000 to up to a maximum aggregate principal amount of $575,003,000 (such increased aggregate principal amount, the "Maximum Tender Cap") of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes").
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
PITTSBURGH , Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") and that UAS has increased the maximum aggregate principal amount for the Maximum Tender Offer from up to a maximum aggregate principal amount of $450,000,000 to up to a maximum aggregate principal amount of $575,003,000 (such increased aggregate principal amount, the "Maximum Tender Cap") of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes").
09/16 16:30 EST - prnewswire.com
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
PITTSBURGH , Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets.
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
PITTSBURGH , Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets.
09/10 19:00 EST - prnewswire.com
Viatris Announces Expiration and Results of Any and All Cash Tender Offers
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No.
Viatris Announces Expiration and Results of Any and All Cash Tender Offers
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No.
09/10 11:40 EST - prnewswire.com
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") and any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes").
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") and any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes").
09/04 03:30 EST - prnewswire.com
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes"), (2) any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes", and the tender offers with respect thereto, the "Any and All Tender Offers") and (3) up to $450,000,000 aggregate principal amount of the outstanding 3.950% Senior Notes due 2026 issued by Utah Acquisition (the "Maximum Tender Offer Notes", and the tender offer with respect thereto, the "Maximum Tender Offer", and the Maximum Tender Offer Notes together with the Any and All Notes, the "Securities").
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes"), (2) any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes", and the tender offers with respect thereto, the "Any and All Tender Offers") and (3) up to $450,000,000 aggregate principal amount of the outstanding 3.950% Senior Notes due 2026 issued by Utah Acquisition (the "Maximum Tender Offer Notes", and the tender offer with respect thereto, the "Maximum Tender Offer", and the Maximum Tender Offer Notes together with the Any and All Notes, the "Securities").
08/23 06:59 EST - prnewswire.com
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH , Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress.
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH , Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress.
08/20 05:30 EST - fool.com
3 Top Value Stocks to Buy Right Now
The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.
3 Top Value Stocks to Buy Right Now
The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.
08/15 10:57 EST - seekingalpha.com
Why Bargain-Priced Viatris Could Deliver Strong Returns
Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive opportunity for income and value investors.
Why Bargain-Priced Viatris Could Deliver Strong Returns
Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive opportunity for income and value investors.
08/09 10:30 EST - zacks.com
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
08/08 13:54 EST - benzinga.com
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
08/08 11:52 EST - fool.com
Why Viatris Stock Is Jumping Today
Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
Why Viatris Stock Is Jumping Today
Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
08/08 10:56 EST - zacks.com
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
08/08 09:10 EST - zacks.com
Viatris (VTRS) Q2 Earnings Surpass Estimates
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
Viatris (VTRS) Q2 Earnings Surpass Estimates
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
08/08 08:40 EST - reuters.com
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
08/08 06:59 EST - prnewswire.com
Viatris Reports Second Quarter Financial Results for 2024
PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2] Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder Return Raises 2024 Full-Year New Product Revenues Range to $500 Million-$600 Million Expects 2024 Full-Year Total Revenues Growth of ~2% on a Divestiture-Adjusted Operational Basis[3] Viatris Inc. (NASDAQ: VTRS) today announced strong financial results for the second quarter of 2024, including total revenues of $3.8 billion and new product revenues of $210 million, demonstrating the Company's ability to continue to grow its diversified base business. With the substantial completion of its divestitures the Company believes it has increased its financial strength and has a strong foundation from which to accelerate growth and shareholder return.
Viatris Reports Second Quarter Financial Results for 2024
PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2] Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder Return Raises 2024 Full-Year New Product Revenues Range to $500 Million-$600 Million Expects 2024 Full-Year Total Revenues Growth of ~2% on a Divestiture-Adjusted Operational Basis[3] Viatris Inc. (NASDAQ: VTRS) today announced strong financial results for the second quarter of 2024, including total revenues of $3.8 billion and new product revenues of $210 million, demonstrating the Company's ability to continue to grow its diversified base business. With the substantial completion of its divestitures the Company believes it has increased its financial strength and has a strong foundation from which to accelerate growth and shareholder return.
08/06 06:59 EST - prnewswire.com
Viatris Announces Second Quarter 2024 Dividend
PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.
Viatris Announces Second Quarter 2024 Dividend
PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.
08/05 16:43 EST - reuters.com
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
08/05 12:41 EST - zacks.com
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
08/05 10:21 EST - zacks.com
Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.